SSSuradech Suthiphosuwan

Suradech Suthiphosuwan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suradech Suthiphosuwan has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Aditya Bharatha

    Division of Neuroradiology, Department of Medical Imaging, Unity Health Toronto–St. Michael’s Hospital, University of Toronto, 30 Bond St, Toronto, ON, Canada M5B 1W8

    10 shared publications
  • Aditya Bharatha

    Department of Medical Imaging, St. Michael’s Hospital, Unity Health Toronto, Toronto, ON, Canada; Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    9 shared publications
  • Jiwon Oh

    Division of Neurology, Department of Medicine, St. Michael’s Hospital, The University of Toronto, Toronto, Canada

    6 shared publications
  • Jiwon Oh

    Division of Neurology, Department of Medicine, St. Michael’s Hospital, Unity Health Toronto, University of Toronto, Toronto, ON, Canada; Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA

    5 shared publications
  • Charlie Chia-Tsong Hsu

    Division of Neuroradiology, Department of Medical Imaging, Gold Coast University Hospital, Australia

    4 shared publications
  • Daniel S. Reich

    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD

    4 shared publications

Latest Publications

  • How I Do It: An Imaging Approach and Review of Autoimmune Encephalitis

    by Vivek Pai, Caroline Rutten, Manohar Shroff, Heejun Kang, Suradech Suthiphosuwan, Alexandre Boutet, E. Ann Yeh, Helen M. Branson, Birgit Betina Ertl-Wagner

    This article addresses autoimmune encephalitis, a potentially devastating immune-mediated central nervous system disorder, and its diverse radiologic manifestations, broadly including limbic and extralimbic involvement.

  • Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study

    by Alexandra Scharf, Jeffrey A. Cohen, Ruth Ann Marrie, Aaron E. Miller, Emmanuelle Waubant, Meghan Kilbane, Elaina Luskin, Christina J. Azevedo, Meredith Dever, Enrique Alvarez, et al.

    The 2024 McDonald criteria allow diagnosis of multiple sclerosis (MS) in individuals presenting with symptoms not specific for MS or incidental imaging findings suggestive of demyelination when supported by biomarker evidence, reflecting a shift toward diagnostic definitions increasingly grounded in biological mechanisms of disease. The diagnostic yield of these criteria in such populations has not been evaluated in multicenter cohorts. We aimed to determine the proportion of individuals with nonspecific or incidental imaging presentations who meet the 2024 McDonald criteria and describe the contribution of central vein sign and cerebrospinal fluid (CSF) oligoclonal bands (OCBs) to diagnostic classification. This cross-sectional post-hoc analysis used data from the Central Vein Sign in Multiple Sclerosis (CAVS-MS) study, a multicenter observational cohort. Adults aged 18–65 years referred for diagnostic evaluation of possible MS were adjudicated by an expert panel (eFigure1). This analysis focused on participants with symptoms not specific for MS or incidental imaging findings suggestive of demyelination. Dissemination in space (DIS) and time (DIT) were assessed using 2017 MRI criteria. Fulfillment of the 2024 McDonald criteria at baseline—the primary outcome—was determined using the Select-6 central vein sign and CSF OCBs. Select-6 assessment was available for all participants, whereas OCB data were available for a subset based on prior clinical evaluation. Of 420 participants enrolled, 191 (45%) presented with either nonspecific symptoms (n=166) or incidental imaging findings (n=25). Mean age was 42 years, and 78% were female. Thirty-six (19%) met the 2024 McDonald criteria at baseline, including 28 (17%) in the nonspecific symptom cohort and 8 (32%) in the incidental imaging cohort. Among 51 participants meeting 2017 DIS, 22 (43%) were Select-6 positive, 17 (33%) had positive OCBs, and 4 (8%) met 2017 DIT. Nonspecific sensory symptoms, visual disturbances, and subacute cognitive decline were most associated with a diagnosis of MS. Application of the 2024 McDonald criteria identified nearly one-fifth of individuals without typical presentations as meeting diagnostic criteria for MS at baseline. Biomarker incorporation—particularly the central vein sign—accounted for a substantial proportion of diagnostic yield. Interpretation is limited by availability of CSF data and absence of longitudinal follow-up.


  • Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice

    by Suradech Suthiphosuwan, Timothy Reynold Lim, Fasna Raufdeen, Minth Punpichet, Amy Wei Lin, Shobhit Mathur, Yingming Amy Chen, Aditya Bharatha, Jiwon Oh

    Background: Monitoring radiologic disease activity (RDA) is standard of care in multiple sclerosis (MS) because new lesions on magnetic resonance imaging (MRI) are associated with adverse outcomes and frequently prompt treatment reassessment and optimization. Coregistration-fusion comparison (CF) is more sensitive than conventional side-by-side comparison (CS) for detecting new lesions. Objectives: To apply CF to identify CS-missed RDA on brain MRIs originally reported as “stable” and to evaluate whether CS-missed RDA predicts future disease activity. Methods: This retrospective cohort included 314 people with MS (pwMS) with three consecutive brain MRIs: previous MRI (t 1 ), index MRI (t 2 ; reported “stable” on CS), and subsequent MRI (t 3 ). CF was applied to three-dimensional Fluid-Attenuated Inversion Recovery (FLAIR) to identify CS-missed new lesions on t 2 versus t 1 . Future RDA was defined as ⩾1 new lesion on t 3 versus t 2 . Clinical disease activity (CDA) was defined as clinical relapse and/or confirmed disability progression during follow-up after t 2 . Results: CF identified 183 CS-missed new lesions in 65/314 pwMS (20.7%). Future RDA (70.8% vs. 16.1%; p < 0.001) and CDA (20.0% vs. 10.0%; p = 0.028) were more frequent in the CS-missed lesion group. Relapse and disability progression, when analyzed separately, did not differ between groups. CS-missed RDA independently predicted future RDA (adjusted odds ratio (aOR) = 10.43; 95% confidence interval (CI) = 5.31–20.46, p < 0.001) and CDA (aOR = 2.49; 95% CI = 1.10–5.65, p = 0.029). Each additional missed lesion at t 2 was associated with more new lesions at t 3 (incidence rate ratio (IRR) = 1.205; 95% CI = 1.184–1.226, p < 0.001). Conclusion: CF reclassified one in five pwMS reported as “stable” on CS as having CS-missed RDA, which predicted future disease activity.

  • Conventional and Emerging MRI Biomarkers of Multiple Sclerosis

    by Timothy Reynold Lim, Jerald Garvin Lim, Yusuf Alibrahim, Minth Punpichet, Aditya Bharatha, Erin S. Beck, Martina Absinta, Daniel S. Reich, Jiwon Oh, Suradech Suthiphosuwan

    Emerging MRI biomarkers of multiple sclerosis that directly correlate with underlying pathophysiologic processes hold great promise for improving diagnostic specificity and prognostication.


  • Choroid plexus enlargement correlates with demyelinating lesions and thalamic atrophy in radiologically isolated syndrome

    by Suradech Suthiphosuwan, Timothy Reynold Lim, Zixuan Hu, Errol Colak, Lisa Eunyoung Lee, Melanie Guenette, Uten Yarach, Nontharat Tucksinapinunchai, Aditya Bharatha, Jiwon Oh

    Background: Choroid plexus (ChP) enlargement correlates with neuroinflammation, brain atrophy, and disability in multiple sclerosis (MS); its relevance in people with radiologically isolated syndrome (pwRIS) is unclear. Objective: To investigate ChP volume (ChPvol) differences across age-/sex-matched pwRIS, people with MS (pwMS), and healthy controls (HCs), and to examine associations between ChPvol, brain volumetric measures, and development of clinically definite MS (CDMS). Methods: 3 Tesla magnetic resonance imagings (3T-MRIs) from 59 pwRIS, 59 pwMS, and 59 HCs were analyzed. ChPvol, white matter lesion volume (WMLvol), central vein sign (CVS), paramagnetic rim lesions (PRLs), and brain volumes were assessed. pwRIS were prospectively monitored for CDMS. Results: ChPvol was larger in pwRIS ( p < 0.0001) and pwMS ( p = 0.042) compared to HCs. Multivariable regression showed that higher ChPvol (odds ratio (OR) = 7.21, 95% confidence interval (CI) = 1.44–36.03, p = 0.016) and lower thalamic volume (OR = 0.23, 95% CI = 0.10–0.52, p < 0.001) independently distinguished RIS from HCs. In pwRIS, ChP enlargement correlated with higher WMLvol ( r s = 0.495, p < 0.0001), higher proportion of CVS-positive lesions ( r s = 0.28, p = 0.042), and lower thalamic volume ( r s = −0.451, p < 0.0001). Of 35 pwRIS with longitudinal follow-up, 10 (28.6%) developed CDMS; however, baseline ChPvol did not differ between those who developed CDMS and those who did not ( p = 0.77). Conclusions: ChP enlargement is evident at the earliest stage of MS, is associated with demyelination and neurodegeneration, highlighting ChP volume as a potential diagnostic biomarker. Although baseline ChPvol alone did not predict progression to CDMS, its similarity in RIS and MS cohorts supports the forthcoming 2024 revised McDonald criteria suggesting that RIS can be considered MS in specific situations.


  • Recurrent Cortical Encephalitis-Like MRI Lesion in European Descent Patient with Neuronal Intranuclear Inclusion Disease

    by Suradech Suthiphosuwan, Timothy Reynold Lim, David G. Munoz, David Fam, Julian Spears, Aditya Bharatha, Elaine Guo Yan Chew, Jia Nee Foo, Weng Khong Lim, Tchoyoson Lim, et al.

  • Low-Field (64 mT) Portable MRI for Rapid Point-of-Care Diagnosis of Dissemination in Space in Patients Presenting with Optic Neuritis

    by Timothy Reynold Lim, Suradech Suthiphosuwan, Jonathan Micieli, Reza Vosoughi, Raphael Schneider, Amy W. Lin, Yingming Amy Chen, Alexandra Muccilli, James J. Marriott, Daniel Selchen, et al.

    BACKGROUND AND PURPOSE: Low-field 64mT portable brain MRI (pMRI) has recently shown diagnostic promise for MS. This study aimed to evaluate the utility of pMRI in assessing dissemination in space (DIS) in patients presenting with optic neuritis and determine whether deploying pMRI in the MS clinic can shorten the time from symptom onset to MRI. MATERIALS AND METHODS: Newly diagnosed optic neuritis patients referred to a tertiary academic MS center from July 2022 to January 2024 underwent both point-of-care pMRI and subsequent conventional 3T MRI (cMRI). Images were evaluated for periventricular (PV), juxtacortical (JC) and infratentorial (IT) lesions. DIS was determined on brain MRI per 2017 McDonald criteria. Test characteristics were computed using cMRI as the reference. Interrater and intermodality agreement between pMRI and cMRI were evaluated using Cohen’s kappa. Time from symptom onset to pMRI and cMRI during the study period was compared to the preceding 1.5 years before pMRI implementation using Kruskal-Wallis with post-hoc Dunn’s tests. RESULTS: Twenty patients (median age: 32.5 [IQR, 28-40]; 80% females) were included, of whom 9 (45%) and 5 (25%) had DIS on cMRI and pMRI, respectively. Median time interval between pMRI and cMRI was 7 days (IQR, 3.5-12.5). Interrater agreement was very good for PV (95%, κ=0.89), and good for JC and IT lesions (90%, κ=0.69 for both). Intermodality agreement was good for PV (90%, κ=0.80) and JC (85%, κ=0.63), and moderate for IT lesions (75%, κ=0.42) and DIS (80%, κ=0.58). pMRI had a sensitivity of 56% and specificity of 100% for DIS. The median time from symptom onset to pMRI was significantly shorter (8.5 days [IQR 7-12]) compared to the interval to cMRI before pMRI deployment (21 days [IQR 8-49], n=50) and after pMRI deployment (15 days [IQR 12-29], n=30) (both p<0.01). Time from symptom onset to cMRI in those periods was not significantly different (p=0.29). CONCLUSIONS: In optic neuritis patients, pMRI exhibited moderate concordance, moderate sensitivity and high specificity for DIS compared to cMRI. Its integration into the MS clinic reduced the time from symptom onset to MRI. Further studies are warranted to evaluate the role of pMRI in expediting early MS diagnosis and as an imaging tool in resource-limited settings. ABBREVIATIONS: pMRI = portable MRI; cMRI = conventional MRI; pwMS = patients with MS; PV = periventricular; JC= juxtacortical; IT = infratentorial; DIS = dissemination in space


  • Epstein-Barr Virus–Associated Smooth-Muscle Tumor of the Brain

    by Afra Alfalahi, Abdelsimar Il Omar, Krystal Fox, Julian Spears, Malika Sharma, Aditya Bharatha, David G. Munoz, Suradech Suthiphosuwan

    SUMMARY: Epstein-Barr virus, a herpesvirus, has been associated with a variety of cancers, including Burkitt, Hodgkin, and non-Hodgkin lymphomas; posttransplant lymphoproliferative disorders; gastric carcinoma; and nasopharyngeal carcinoma, in both immunocompetent and immunocompromised individuals. Previous studies have established a connection between Epstein-Barr virus and the development of smooth-muscle tumors. Smooth-muscle tumors of the brain are very rare and are often misdiagnosed as meningiomas on imaging. To our knowledge, advanced imaging findings such as MR perfusion of smooth-muscle tumors of the brain have never been reported. We describe the radiologic and pathologic features of the Epstein-Barr virus–associated smooth-muscle tumors of the brain in a person with newly diagnosed advanced HIV.


  • Open Access

    Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury

    by Vivek Pai, Heejun Kang, Suradech Suthiphosuwan, Andrew Gao, Daniel Mandell, Manohar Shroff

    Pai V, et al. Korean J Radiol. 2024 Sep;25(9):807-823. https://doi.org/10.3348/kjr.2023.1307